(News Bulletin 247) – The Danish pharmaceutical group Novo Nordisk announced Thursday that it had reached an agreement to buy the Canadian biotechnology company Inversago for an amount that could reach 1.075 million dollars in cash.
Based in Montreal, Inversago specializes in the development of therapies targeting inhibition of the CB1 receptor using a new class of peripherally active inverse agonists.
The company aims to develop new therapeutic options in the treatment of several metabolic disorders, such as diabetes or NASH.
In a press release, Novo explains that it intends to take an interest in INV-202, Inversago’s lead candidate, in the treatment of obesity and obesity-related complications.
The acquisition of Inversago, which employs 22 people, should be completed by the end of the year.
Listed on the Copenhagen Stock Exchange, Novo Nordisk shares fell 1.7% on Thursday following the publication of second-quarter results that came out slightly below market forecasts.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
